Table of Contents
Jefferies Global Healthcare Conference in London
Date: November 17-20, 2025
To view the webcast, please click here.
Jefferies Global Healthcare Conference in London
Related
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results
About Media Contact Legal → Download PDF Corporate Overview Ocugen, Inc. About Ocugen, Inc. ▼ Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike
Affinia Therapeutics Granted FDA Fast Track Designation for AFTX-201 as a Treatment for People Living with BAG3-Associated Dilated Cardiomyopathy (DCM)
✨ Onyx Summary Affinia Therapeutics announced that the U.S. Food and Drug Administration has granted Fast Track designation to AFTX-201, its investigational gene therapy for BAG3-associated dilated cardiomyopathy, which is currently being evaluated in the Phase 1/2 UPBEAT clinical trial. The designation signals regulatory support for accelerating development of
Belite Bio to Host Webcast on March 2, 2026, to Discuss Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results
✨ Onyx Summary Belite Bio announced it will host a webcast on March 2, 2026 at 4:30 p.m. ET to discuss fourth-quarter and full-year 2025 financial results and provide a business update. A live webcast and a replay (available for about 90 days) will be accessible via the company’
Affinia Therapeutics Receives European Medicines Agency Orphan Drug Designation for AFTX-201 in BAG3-Associated Dilated Cardiomyopathy (DCM)
✨ Onyx Summary Affinia Therapeutics said the European Medicines Agency has granted Orphan Drug designation to AFTX-201, its investigational AAV gene therapy for BAG3-associated dilated cardiomyopathy, following the FDA’s acceptance of its IND. The designation adds regulatory incentives and market-exclusivity potential in the EU as Affinia advances a one-time intravenous
Comments